Advanced glycation end products (AGE) and diabetes: cause, effect, or both?
- PMID: 24292971
- PMCID: PMC3903318
- DOI: 10.1007/s11892-013-0453-1
Advanced glycation end products (AGE) and diabetes: cause, effect, or both?
Abstract
Despite new and effective drug therapies, insulin resistance (IR), type 2 diabetes mellitus (T2D) and its complications remain major medical challenges. It is accepted that IR, often associated with over-nutrition and obesity, results from chronically elevated oxidant stress (OS) and chronic inflammation. Less acknowledged is that a major cause for this inflammation is excessive consumption of advanced glycation end products (AGEs) with the standard western diet. AGEs, which were largely thought as oxidative derivatives resulting from diabetic hyperglycemia, are increasingly seen as a potential risk for islet β-cell injury, peripheral IR and diabetes. Here we discuss the relationships between exogenous AGEs, chronic inflammation, IR, and T2D. We propose that under chronic exogenous oxidant AGE pressure the depletion of innate defense mechanisms is an important factor, which raises susceptibility to inflammation, IR, T2D and its complications. Finally we review evidence on dietary AGE restriction as a nonpharmacologic intervention, which effectively lowers AGEs, restores innate defenses and improves IR, thus, offering new perspectives on diabetes etiology and therapy.
Conflict of interest statement
Helen Vlassara has received grant support and support for travel to meetings for the study or otherwise from Sanofi for a co-investigator-initiated clinical investigation. She has patents (planned, pending or issued) from Cell Biolabs for development of monoclonal antibody, and receives royalties for monoclonal antibody. Her husband is principal investigator in investigator-initiated clinical trial, supported by Sanofi.
Jaime Uribarri is a co-author on a book on AGE-less Diet.
Figures
References
-
- Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14 (Suppl 5):S1–85. - PubMed
-
- Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE. Diabetes and advanced glycoxidation end products. Diabetes Care. 2006;29:1420–32. - PubMed
-
- Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults Diabetes Care. 2004;27:2444–9. - PubMed
-
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86. No authors listed. - PubMed
-
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854–65. No authors listed. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
